A Single Probiotic Strain Reduced Depression Markers in Mice. Here’s the Mechanism.

Depression affects hundreds of millions of people worldwide, yet current antidepressants still fail a large share of patients, often taking weeks to work and carrying side effects that push many to stop treatment. A new study published in Food & Function by Dou F and colleagues offers an early but detailed look at how a single probiotic strain, Lactiplantibacillus plantarum KLDS1.0344, reduced depressive-like behavior in chronically stressed mice. The mechanism, mapped through combined gut microbiome and metabolomics data, points toward sphingolipid and glycerophospholipid pathways as potential intermediaries between gut bacteria and brain chemistry. This is preliminary, mouse-model research, and it should be read that way. But the mechanistic detail is unusually granular for a preclinical psychobiotic study.

KLDS1.0344 Cut Stress Hormones and Partly Restored Dopamine and Serotonin

The core finding is dose-dependent: high-dose KLDS1.0344 produced the most pronounced effects across multiple behavioral tests, including open field, tail suspension, forced swim, and sucrose preference assays. Mice in the high-dose group showed meaningful reductions in the three key hormones of the hypothalamic-pituitary-adrenal (HPA) axis: corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone. An overactive HPA axis is one of the most consistently replicated biological features of depression in both rodents and humans, so lowering all three markers simultaneously is a notable result. On the neurotransmitter side, dopamine, norepinephrine, and 5-hydroxytryptamine (5-HT, or serotonin) were all partially restored in probiotic-treated animals. Brain-derived neurotrophic factor (BDNF), a protein linked to neuronal resilience and often depleted in depression, also rebounded. None of these changes reached full normalization, but the directional consistency across behavioral, hormonal, and neurochemical endpoints gives the finding more coherence than a single-measure result would.

Gut Microbiota Remodeling as a Route to Mood Improvement

What makes the study mechanistically interesting is its attempt to trace how an oral probiotic produces changes in the brain. At high doses, KLDS1.0344 remodeled the gut microbiota, most notably restoring populations of Lactobacillus that had been depleted by chronic stress. This matters because a randomized, double-blind, placebo-controlled human trial of Lactiplantibacillus plantarum DR7 previously showed that strains from this genus can reduce cortisol and anxiety scores in stressed adults, lending biological plausibility to the rodent findings. L. plantarum strains are known to produce compounds including gamma-aminobutyric acid (GABA), tryptophan metabolites, and short-chain fatty acids (SCFAs), all of which can signal along the gut-brain axis. The strain also produces butyrate, a short-chain fatty acid that can strengthen the intestinal barrier and upregulate BDNF expression in the brain. A broader meta-analysis of randomized clinical trials found that probiotics significantly reduced depression and anxiety in participants, with the strongest effects in those with milder symptoms, suggesting the gut-mood connection has some clinical grounding even if the specific lipid pathway identified here remains unverified in humans.

How Multi-Omics Exposed the Sphingolipid and Glycerophospholipid Connection

The methodological move that elevates this study above a simple behavioral intervention is the integration of 16S rRNA gene sequencing with untargeted metabolomics of intestinal contents. That combination, reviewed as a foundational approach in multi-omics research on the gut-brain axis, allowed the researchers to correlate specific shifts in microbial community structure with changes in metabolite profiles. The two pathways that emerged most prominently were sphingolipid metabolism and glycerophospholipid metabolism. Both lipid classes have known roles in neuroinflammation, membrane signaling, and neurotransmitter regulation. The correlation analysis showed that the taxa restored by KLDS1.0344 were associated with the most significant metabolite shifts, pointing toward a coordinated microbiota-metabolite framework rather than independent, parallel effects. That framework is still a hypothesis, not a proven causal chain, but it gives researchers a specific biological target to pursue in follow-up work.

The chronic unpredictable mild stress model used here is the field standard for inducing depression-like states in rodents. Exposing mice to rotating, unpredictable stressors over several weeks reliably produces anhedonia, behavioral despair, and HPA dysregulation that mirror clinical depression. The four behavioral tests used, open field for locomotion and anxiety, tail suspension and forced swim for behavioral despair, and sucrose preference for anhedonia, are also well-validated and commonly used together to cross-confirm findings. That methodological rigor matters when evaluating whether the behavioral improvements are real within the model, even if translation to humans remains uncertain.

Translating Mouse Microbiome Findings to Humans Remains an Open Problem

The most significant limitation here is the one the authors acknowledge directly: this is a mouse study. Translating gut microbiota findings from rodents to humans is notoriously difficult. The murine microbiome differs substantially from the human microbiome in composition and function, and the controlled, germ-reduced housing conditions of laboratory mice amplify effects that may be far smaller in the diverse microbial environments of real human guts. The CUMS model also compresses chronic stress into weeks, while human depression typically develops over months or years under more complex social and environmental conditions. Probiotic efficacy is also highly strain-specific, meaning results with KLDS1.0344 do not generalize to other L. plantarum strains or to probiotics broadly. Distinguishing true psychobiotic effects from general improvements in gut health is a persistent methodological challenge the researchers flag but cannot fully resolve with the current design.

Personalized Psychobiotics and the Road Toward Human Trials

360 million people live with depression globally, and the gap between animal model findings and clinically actionable treatments is wide. The future of psychobiotic therapy likely requires integrating multi-omics datasets with individual host factors, the kind of personalized approach that this study gestures toward but cannot yet deliver. The immediate next steps are clear: mechanistic studies to confirm whether the sphingolipid and glycerophospholipid pathway changes are causal rather than correlational, followed by carefully designed human trials that can account for baseline microbiome variability across individuals. The authors also suggest KLDS1.0344 has potential as an ingredient in functional foods targeting depression-related symptoms, a lower regulatory bar than a pharmaceutical intervention. That path is realistic only if human data eventually support the strain's safety and efficacy profile. For now, KLDS1.0344 joins a growing list of probiotic candidates with compelling preclinical profiles and a long road ahead before they reach a clinical recommendation.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• This study was conducted entirely in mice — results have not been tested in humans.
• Association between gut microbiota changes and behavioral improvement does not establish causation; the proposed microbiota-metabolite mechanism remains a candidate framework.
• Findings have not yet been independently replicated in a separate laboratory or population.
• Funding source was not disclosed by the authors.

Preclinical murine study using a chronic unpredictable mild stress model with multi-omics integration (16S rRNA sequencing and untargeted metabolomics). Results show association between probiotic treatment and behavioral and neurochemical changes, but cannot establish causation, and the proposed microbiota-metabolite mechanism requires further validation. Not yet replicated in an independent study or human population.

References

1. Fangfei Dou, Yuxing Li, Wenqing Lv, et al. (2026). Lactiplantibacillus plantarum KLDS1.0344 ameliorates depressive-like behavior in CUMS mice: integrative multi-omics evidence linking gut microbiota alterations to sphingolipid and glycerophospholipid metabolic pathways. Food & Function. https://doi.org/10.1039/d6fo00143b
2. H.X. Chong, N.A. A. Yusoff, Y.-Y. Hor, et al. (2019). Lactobacillus plantarum DR7 alleviates stress and anxiety in adults: a randomised, double-blind, placebo-controlled study. Beneficial Microbes. https://doi.org/10.3920/bm2018.0135
3. The Effect of Prebiotics and Probiotics on Levels of Depression, Anxiety, and Cognitive Function: A Meta‐Analysis of Randomized Clinical Trials – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10903328/
4. Joshua B Simpson, Matthew R Redinbo (2022). Multi-omic analysis of host-microbial interactions central to the gut-brain axis. Molecular Omics. https://doi.org/10.1039/d2mo00205a
5. Ghofran Khalid Alqurashi, Emad A. Hindi, Mohamed A. Zayed, et al. (2022). The Impact of Chronic Unpredictable Mild Stress-Induced Depression on Spatial, Recognition and Reference Memory Tasks in Mice: Behavioral and Histological Study. Behavioral Sciences. https://doi.org/10.3390/bs12060166
6. Sofia D. Forssten, Arthur C. Ouwehand, Síle M. Griffin, Elaine Patterson (2022). One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials. Nutrients. https://doi.org/10.3390/nu14030568
7. Gilberto Uriel Rosas-Sánchez, José Luis Muñoz-Carrillo, Cesar Soria-Fregozo (2025). Transforming mental health: the future of personalized psychobiotics in anxiety and depression therapy. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2025.1711846